Sandbox/v20: Difference between revisions

Jump to navigation Jump to search
(Created page with " ====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin==== {| |- | valign=top | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: lef...")
 
Line 1: Line 1:


{{Meningitis}}


====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin====
====Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin====
Line 6: Line 8:
|-
|-
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterococcus Susceptible to <BR> Penicillin, Gentamicin, and Vancomycin}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterococcus Susceptible to <BR> Penicillin, Gentamicin, and Vancomycin}}''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)''
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Pediatric)''
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen (Pediatric)''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h x 4—6 weeks''''' <BR> ''OR'' <BR> ▸ '''''[[Penicillin G potassium]] 3—5 million U/day IV q4h x 4—6 weeks'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 4—6 weeks'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''<sup>†</sup>
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''<sup>†</sup>
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Pediatric)''<sup>†</sup>
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Alternative Regimen (Pediatric)''<sup>†</sup>
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q12h x 6 weeks'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 1 mg/kg IV q8h x 6 weeks'''''
|-
|-
|}
|}
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:38em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}<sup>†</sup>''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''


|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 95%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]  8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]  8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
|}
|}
|}
|}
Line 97: Line 99:
<sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected.
<sup>†</sup>Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected.


<SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal  | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 380 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref>
<SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;395(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal  | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 395 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref>

Revision as of 21:27, 15 January 2014


Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment

Enterococcal Strains Susceptible to Penicillin, Gentamicin, and Vancomycin

Enterococcus Susceptible to
Penicillin, Gentamicin, and Vancomycin
Preferred Regimen (Adult)
Ampicillin 2 g IV q4h x 4—6 weeks
OR
Penicillin G potassium 3—5 million U/day IV q4h x 4—6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 4—6 weeks
Preferred Regimen (Pediatric)
Ampicillin 2 g IV q4h x 4—6 weeks
OR
Penicillin G potassium 3—5 million U/day IV q4h x 4—6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 4—6 weeks
Alternative Regimen (Adult)
Vancomycin 15 mg/kg IV q12h x 6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 6 weeks
Alternative Regimen (Pediatric)
Vancomycin 15 mg/kg IV q12h x 6 weeks
PLUS
Gentamicin 1 mg/kg IV q8h x 6 weeks
Adult, Age <50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
to achieve serum trough concentrations of 15–20 μg/mL
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Adult, Age >50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
AND
Ampicillin 2 g IV q4h
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Immunocompromised
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
AND
Ampicillin 2 g IV q4h
AND
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h
Recurrent
Preferred Regimen
Vancomycin 30—60 mg/kg/day IV q8–12h
AND
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h

Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.

Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;395(9854):1693-702.[1]

  1. van de Beek, D.; Brouwer, MC.; Thwaites, GE.; Tunkel, AR. (2012). "Advances in treatment of bacterial meningitis". Lancet. 395 (9854): 1693–702. doi:10.1016/S0140-6736(12)61186-6. PMID 23141618. Unknown parameter |month= ignored (help)